Home › Companies › Pacira Biosciences, Inc. › 2025-2026

Pacira Biosciences, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Pacira Biosciences, Inc.’s Form 8-K, filed 2026-06-11 (Item 5.07 on EDGAR). Page generated 02 October 2026.

22Reported items
283Asset managers
3,666Fund votes
2026-06-09Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Pacira Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Pacira Biosciences, Inc.

These tallies are Pacira Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Pacira Biosciences, Inc. — official shareholder meeting results, meeting held 2026-06-09
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Christopher J. Christie	24,963,961	--	--	7,675,321	--	Majority: yes
Elect Director: Samit Hirawat	27,950,304	--	--	4,688,937	--	Majority: yes
Elect Director: Thomas Wiggans	28,044,841	--	--	4,594,438	--	Majority: yes
Elect Director: Oliver Benton Curtis III	4,614,368	--	--	28,024,482	--	Plurality election
Elect Director: Eric de Armas	4,861,350	--	--	27,777,500	--	Plurality election
Elect Director: Christopher Dennis	4,430,726	--	--	28,208,124	--	Plurality election
Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.	32,908,044	138,246	49,702	--	--	Majority: yes
Proposal 3: Advisory vote to approve the compensation of the Company's named executive officers.	19,513,224	13,073,321	57,010	--	452,437	Majority: yes
Proposal 4: Approval of the Company's Amended and Restated 2011 Stock Incentive Plan.	14,178,418	18,405,754	59,383	--	452,437	Majority: no
Proposal 5: Approval of the Company's Amended and Restated 2014 Employee Stock Purchase Plan.	29,089,928	3,497,653	55,974	--	452,437	Majority: yes

Source: Pacira Biosciences, Inc., Form 8-K, filed with the SEC on 2026-06-11 — read the filing on EDGAR.

How asset managers voted at the Pacira Biosciences, Inc. 2025-2026 meeting

Each item below shows how the 283 asset managers that disclosed a Pacira Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Pacira Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-09.

Combines 2 wordings of this item as funds reported it.

76% fund support · no official result

FOR 76%AGAINST 24%

The 268 asset managers below cast 76% of the shares they voted on this item FOR (20,427,886 for, 6,285,661 against).

FOR: 20,427,886 (76.5%)AGAINST: 6,285,661 (23.5%)NOT VOTED: 61 (0.0%)

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,973,306	2,615	For
BlackRock	4,577,914	39,405	For
State Street	1,759,529	1,899	For
Charles Schwab	1,397,394	0	For
Fidelity	798,367	185,694	For
GEODE CAPITAL MANAGEMENT, LLC	925,042	0	For
Dimensional	0	810,234	Against
IMPAX ASSET MANAGEMENT LLC	750,027	0	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Wellington	460,816	0	For
Invesco	0	460,624	Against
DE Shaw	0	427,335	Against
EA Series Trust	370,428	0	For
Renaissance	0	356,674	Against
DWS	0	355,716	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	350,121	0	For
Northern Trust	0	348,956	Against
LSV ASSET MANAGEMENT	339,400	0	For
Victory Capital	0	337,240	Against
Goldman Sachs	328,393	4,575	For
Hillsdale Investment Management Inc.	0	331,300	Against
PRINCIPAL GLOBAL INVESTORS	0	284,752	Against
World Funds Trust	269,955	0	For
SEI	260,241	0	For
Pacer Funds Trust	234,623	0	For

Showing the 25 largest of 268 asset managers. See all 268 in the interactive database.

2. APPROVAL OF OUR AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-09.

Combines 6 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 29,089,928AGAINST: 3,497,653

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 5: Approval of the Company's Amended and Restated 2014 Employee Stock Purchase Plan.”): 29,089,928 for, 3,497,653 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 74% for, 9% against (83% of the company cast a for/against vote).

The 90 asset managers below cast 84% of the shares they voted on this item FOR (15,905,873 for, 2,959,421 against).

FOR 76%AGAINST 14%10%

FOR: 15,905,873 (75.6%)AGAINST: 2,959,421 (14.1%)ABSTAIN: 3,547 (0.0%)NOT VOTED: 2,121,082 (10.1%)UNVOTED: 43,088 (0.2%)

Largest asset managers voting on “APPROVAL OF OUR AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,584,355	0	For
BlackRock	3,303,017	0	For
Doma Perpetual Capital Management LLC	0	2,769,053	Against
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	662,055	0	For
Fidelity	916,684	0	For
State Street	859,422	0	For
American Century	803,003	0	For
Dimensional	659,669	0	For
EA Series Trust	370,428	0	For
DWS	355,611	0	For
World Funds Trust	269,955	0	For
Pacer Funds Trust	234,623	0	For
Hartford	112,905	0	For
SEI	105,140	0	For
ADVISORS' INNER CIRCLE FUND	72,300	0	For
James Alpha Funds Trust	0	138,400	Against
Columbia Threadneedle	121,655	0	For
Russell Investments	57,348	0	For
Victory Capital	99,540	0	For
EXCHANGE TRADED CONCEPTS TRUST	98,624	0	For
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	93,191	0	For
Lincoln Financial	44,097	0	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	43,088	0	For

Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.

3. APPROVAL OF OUR AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: no

Meeting held 2026-06-09.

Combines 2 wordings of this item as funds reported it.

44% Majority: no · of votes cast

FOR 44%AGAINST 56%

FOR: 14,178,418AGAINST: 18,405,754

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 4: Approval of the Company's Amended and Restated 2011 Stock Incentive Plan.”): 14,178,418 for, 18,405,754 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 36% for, 46.8% against (83% of the company cast a for/against vote).

The 87 asset managers below cast 62% of the shares they voted on this item FOR (9,940,112 for, 6,081,930 against).

FOR 54.8%AGAINST 34%12%

FOR: 9,940,112 (54.8%)AGAINST: 6,081,930 (33.5%)ABSTAIN: 3,547 (0.0%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “APPROVAL OF OUR AMENDED AND RESTATED 2011 STOCK INCENTIVE PLAN.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,808,734	1,775,622	For
BlackRock	3,143,306	159,711	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	0	662,055	Against
Fidelity	798,367	118,317	For
State Street	857,082	2,340	For
American Century	802,513	490	For
Dimensional	0	659,669	Against
EA Series Trust	177,889	192,539	Against
DWS	0	355,611	Against
World Funds Trust	0	269,955	Against
Pacer Funds Trust	0	234,623	Against
Hartford	112,905	0	For
SEI	0	105,140	Against
ADVISORS' INNER CIRCLE FUND	0	72,300	Against
James Alpha Funds Trust	0	138,400	Against
Columbia Threadneedle	0	121,655	Against
Russell Investments	0	57,348	Against
Victory Capital	0	99,540	Against
EXCHANGE TRADED CONCEPTS TRUST	0	98,624	Against
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	58,191	35,000	For
Lincoln Financial	26,875	17,222	Not Voted
Principal Exchange-Traded Funds	0	85,191	Against
TIAA	0	84,558	Against

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

4. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: Samit Hirawat

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-09.

Combines 7 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD 14%

FOR: 27,950,304WITHHELD: 4,688,937

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Samit Hirawat”): 27,950,304 for, 4,688,937 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 71% for, 12% withheld (83% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (14,887,354 for, 0 against).

FOR 82%12%

FOR: 14,887,354 (81.9%)ABSTAIN: 1,162,252 (6.4%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,584,355	0	For
BlackRock	3,303,017	0	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	662,055	0	For
Fidelity	916,684	0	For
State Street	859,422	0	For
American Century	490	802,513	Abstain
Dimensional	659,669	0	For
EA Series Trust	192,539	177,889	For
DWS	355,611	0	For
World Funds Trust	269,955	0	For
Pacer Funds Trust	234,623	0	For
Hartford	112,905	0	For
SEI	105,140	0	For
ADVISORS' INNER CIRCLE FUND	72,300	0	For
James Alpha Funds Trust	0	138,400	Abstain
Columbia Threadneedle	121,655	0	For
Russell Investments	57,348	0	For
Victory Capital	99,540	0	For
EXCHANGE TRADED CONCEPTS TRUST	98,624	0	For
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	93,191	0	For
Lincoln Financial	44,097	0	For
Principal Exchange-Traded Funds	85,191	0	For
TIAA	84,558	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

5. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: Tom Wiggans

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-09.

Combines 7 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD 14%

FOR: 28,044,841WITHHELD: 4,594,438

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Thomas Wiggans”): 28,044,841 for, 4,594,438 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 71% for, 12% withheld (83% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (14,924,523 for, 0 against).

FOR 82%12%

FOR: 14,924,523 (82.1%)ABSTAIN: 1,125,083 (6.2%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,584,355	0	For
BlackRock	3,303,017	0	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	662,055	0	For
Fidelity	916,684	0	For
State Street	859,422	0	For
American Century	490	802,513	Abstain
Dimensional	659,669	0	For
EA Series Trust	192,539	177,889	For
DWS	355,611	0	For
World Funds Trust	269,955	0	For
Pacer Funds Trust	234,623	0	For
Hartford	112,905	0	For
SEI	105,140	0	For
ADVISORS' INNER CIRCLE FUND	72,300	0	For
James Alpha Funds Trust	0	138,400	Abstain
Columbia Threadneedle	121,655	0	For
Russell Investments	57,348	0	For
Victory Capital	99,540	0	For
EXCHANGE TRADED CONCEPTS TRUST	98,624	0	For
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	93,191	0	For
Lincoln Financial	44,097	0	For
Principal Exchange-Traded Funds	85,191	0	For
TIAA	84,558	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

6. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Christopher Dennis

DIRECTOR ELECTIONSCompany result: Plurality election

Meeting held 2026-06-09.

Combines 6 wordings of this item as funds reported it.

14% Plurality election · of votes cast

14%WITHHELD 86%

FOR: 4,430,726WITHHELD: 28,208,124

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Christopher Dennis”): 4,430,726 for, 28,208,124 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here. Of all 39,347,924 outstanding shares: 11% for, 72% withheld (83% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (984,363 for, 0 against).

ABSTAIN 83%12%

FOR: 984,363 (5.4%)ABSTAIN: 15,065,243 (82.9%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	0	4,584,355	Abstain
BlackRock	0	3,303,017	Abstain
IMPAX FUNDS SERIES TRUST I	0	750,027	Abstain
Charles Schwab	0	662,055	Abstain
Fidelity	0	916,684	Abstain
State Street	0	859,422	Abstain
American Century	802,513	490	For
Dimensional	0	659,669	Abstain
EA Series Trust	0	370,428	Abstain
DWS	0	355,611	Abstain
World Funds Trust	0	269,955	Abstain
Pacer Funds Trust	0	234,623	Abstain
Hartford	0	112,905	Abstain
SEI	0	105,140	Abstain
ADVISORS' INNER CIRCLE FUND	0	72,300	Abstain
James Alpha Funds Trust	138,400	0	For
Columbia Threadneedle	0	121,655	Abstain
Russell Investments	0	57,348	Abstain
Victory Capital	0	99,540	Abstain
EXCHANGE TRADED CONCEPTS TRUST	0	98,624	Abstain
NYLIM VP FUNDS TRUST	0	47,744	Abstain
Equitable	0	93,191	Abstain
Lincoln Financial	0	44,097	Abstain
Principal Exchange-Traded Funds	0	85,191	Abstain
TIAA	0	84,558	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

7. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Eric de Armas

DIRECTOR ELECTIONSCompany result: Plurality election

Meeting held 2026-06-09.

Combines 6 wordings of this item as funds reported it.

15% Plurality election · of votes cast

FOR 15%WITHHELD 85%

FOR: 4,861,350WITHHELD: 27,777,500

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Eric de Armas”): 4,861,350 for, 27,777,500 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here. Of all 39,347,924 outstanding shares: 12% for, 71% withheld (83% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (1,165,884 for, 0 against).

ABSTAIN 82%12%

FOR: 1,165,884 (6.4%)ABSTAIN: 14,883,722 (81.9%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	0	4,584,355	Abstain
BlackRock	159,711	3,143,306	Abstain
IMPAX FUNDS SERIES TRUST I	0	750,027	Abstain
Charles Schwab	0	662,055	Abstain
Fidelity	27,855	888,829	Abstain
State Street	0	859,422	Abstain
American Century	802,513	490	For
Dimensional	0	659,669	Abstain
EA Series Trust	0	370,428	Abstain
DWS	0	355,611	Abstain
World Funds Trust	0	269,955	Abstain
Pacer Funds Trust	0	234,623	Abstain
Hartford	0	112,905	Abstain
SEI	0	105,140	Abstain
ADVISORS' INNER CIRCLE FUND	0	72,300	Abstain
James Alpha Funds Trust	138,400	0	For
Columbia Threadneedle	0	121,655	Abstain
Russell Investments	0	57,348	Abstain
Victory Capital	0	99,540	Abstain
EXCHANGE TRADED CONCEPTS TRUST	0	98,624	Abstain
NYLIM VP FUNDS TRUST	0	47,744	Abstain
Equitable	0	93,191	Abstain
Lincoln Financial	0	44,097	Abstain
Principal Exchange-Traded Funds	0	85,191	Abstain
TIAA	0	84,558	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

8. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Oliver Benton Curtis III

DIRECTOR ELECTIONSCompany result: Plurality election

Meeting held 2026-06-09.

Combines 7 wordings of this item as funds reported it.

14% Plurality election · of votes cast

FOR 14%WITHHELD 86%

FOR: 4,614,368WITHHELD: 28,024,482

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Oliver Benton Curtis III”): 4,614,368 for, 28,024,482 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here. Of all 39,347,924 outstanding shares: 12% for, 71% withheld (83% of the company cast a for/withheld vote).

The 87 asset managers below cast 100% of the shares they voted on this item FOR (984,363 for, 0 against).

ABSTAIN 83%12%

FOR: 984,363 (5.4%)ABSTAIN: 15,065,243 (82.9%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	0	4,584,355	Abstain
BlackRock	0	3,303,017	Abstain
IMPAX FUNDS SERIES TRUST I	0	750,027	Abstain
Charles Schwab	0	662,055	Abstain
Fidelity	0	916,684	Abstain
State Street	0	859,422	Abstain
American Century	802,513	490	For
Dimensional	0	659,669	Abstain
EA Series Trust	0	370,428	Abstain
DWS	0	355,611	Abstain
World Funds Trust	0	269,955	Abstain
Pacer Funds Trust	0	234,623	Abstain
Hartford	0	112,905	Abstain
SEI	0	105,140	Abstain
ADVISORS' INNER CIRCLE FUND	0	72,300	Abstain
James Alpha Funds Trust	138,400	0	For
Columbia Threadneedle	0	121,655	Abstain
Russell Investments	0	57,348	Abstain
Victory Capital	0	99,540	Abstain
EXCHANGE TRADED CONCEPTS TRUST	0	98,624	Abstain
NYLIM VP FUNDS TRUST	0	47,744	Abstain
Equitable	0	93,191	Abstain
Lincoln Financial	0	44,097	Abstain
Principal Exchange-Traded Funds	0	85,191	Abstain
TIAA	0	84,558	Abstain

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

9. RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-09.

Combines 3 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 32,908,044AGAINST: 138,246

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 32,908,044 for, 138,246 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 84% for, 0.4% against (84% of the company cast a for/against vote).

The 87 asset managers below cast 99.9% of the shares they voted on this item FOR (16,049,519 for, 88 against).

FOR 88%12%

FOR: 16,049,519 (88.3%)AGAINST: 88 (0.0%)NOT VOTED: 2,121,082 (11.7%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	4,584,355	0	For
BlackRock	3,303,017	0	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	662,055	0	For
Fidelity	916,684	0	For
State Street	859,334	88	For
American Century	803,003	0	For
Dimensional	659,669	0	For
EA Series Trust	370,428	0	For
DWS	355,611	0	For
World Funds Trust	269,955	0	For
Pacer Funds Trust	234,623	0	For
Hartford	112,905	0	For
SEI	105,140	0	For
ADVISORS' INNER CIRCLE FUND	72,300	0	For
James Alpha Funds Trust	138,400	0	For
Columbia Threadneedle	121,655	0	For
Russell Investments	57,348	0	For
Victory Capital	99,540	0	For
EXCHANGE TRADED CONCEPTS TRUST	98,624	0	For
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	93,191	0	For
Lincoln Financial	44,097	0	For
Principal Exchange-Traded Funds	85,191	0	For
TIAA	84,558	0	For

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.

10. Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: Christopher J. Christie

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-09.

Combines 6 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 24,963,961WITHHELD: 7,675,321

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Christopher J. Christie”): 24,963,961 for, 7,675,321 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 63% for, 20% withheld (83% of the company cast a for/withheld vote).

The 83 asset managers below cast 100% of the shares they voted on this item FOR (14,061,115 for, 0 against).

FOR 79%9%12%

FOR: 14,061,115 (78.8%)ABSTAIN: 1,656,083 (9.3%)NOT VOTED: 2,121,082 (11.9%)

Largest asset managers voting on “Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stoc” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,584,355	0	For
BlackRock	3,143,306	0	For
IMPAX FUNDS SERIES TRUST I	750,027	0	For
Charles Schwab	662,055	0	For
Fidelity	888,829	27,855	For
State Street	859,422	0	For
American Century	490	802,513	Abstain
Dimensional	0	659,669	Abstain
EA Series Trust	370,428	0	For
DWS	355,611	0	For
World Funds Trust	269,955	0	For
Pacer Funds Trust	234,623	0	For
Hartford	112,905	0	For
SEI	105,140	0	For
ADVISORS' INNER CIRCLE FUND	72,300	0	For
Columbia Threadneedle	121,655	0	For
Russell Investments	57,348	0	For
Victory Capital	99,540	0	For
EXCHANGE TRADED CONCEPTS TRUST	98,624	0	For
NYLIM VP FUNDS TRUST	47,744	0	For
Equitable	93,191	0	For
Lincoln Financial	37,604	6,493	Not Voted
Principal Exchange-Traded Funds	85,191	0	For
TIAA	84,558	0	For
Jackson National	63,944	11,153	For

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

11. Approval, on an advisory basis, of the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-09.

Combines 3 wordings of this item as funds reported it.

70% fund support · no official result

FOR 21%9%NOT VOTED 70%

The 76 asset managers below cast 70% of the shares they voted on this item FOR (1,676,385 for, 732,442 against).

FOR: 1,676,385 (20.9%)AGAINST: 732,442 (9.1%)ABSTAIN: 4,536 (0.1%)NOT VOTED: 5,612,174 (69.9%)NO VOTE: 500 (0.0%)

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of the Company's named executive officers.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
American Century	1,668,389	0	For
Charles Schwab	0	0	Not Voted
IMPAX ASSET MANAGEMENT LLC	0	0	Not Voted
IMPAX FUNDS SERIES TRUST I	0	0	Not Voted
Wellington	0	0	Not Voted
BlackRock	0	458,861	Against
Renaissance	0	0	Not Voted
LSV ASSET MANAGEMENT	0	0	Not Voted
SEI	0	0	Not Voted
Vanguard	0	0	Not Voted
James Alpha Funds Trust	0	138,400	Against
Russell Investments	0	0	Not Voted
Hartford	0	0	Not Voted
RICE HALL JAMES & ASSOCIATES, LLC	0	0	Not Voted
Universal-Investment-Gesellschaft mbH	0	0	Not Voted
ADVISORS' INNER CIRCLE FUND	0	0	Not Voted
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	0	0	Not Voted
NEW YORK STATE COMMON RETIREMENT FUND	0	0	Not Voted
Prudential/PGIM	0	0	Not Voted
Robeco Institutional Asset Management B.V.	0	0	Not Voted
AllianceBernstein	0	0	Not Voted
NYLIM VP FUNDS TRUST	0	0	Not Voted
Lincoln Financial	0	0	Not Voted
Rhumbline	1,715	36,342	Against
WASHINGTON STATE INVESTMENT BOARD	0	0	Not Voted

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

12. COMPANY NOMINEE OPPOSED BY DOMA: Christopher J. Christie

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-09.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 24,963,961WITHHELD: 7,675,321

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ABSTAIN 100%

ABSTAIN: 332,408 (100.0%)

Largest asset managers voting on “COMPANY NOMINEE OPPOSED BY DOMA: Christopher J. Christie” at Pacira Biosciences, Inc., 2025-2026
Asset manager	Abstain	Vote
BlackRock	159,711	Abstain
James Alpha Funds Trust	138,400	Abstain
MASTER INVESTMENT PORTFOLIO	18,144	Abstain
RBB FUND, INC.	12,980	Abstain
TRUST FOR PROFESSIONAL MANAGERS	3,173	Abstain
ETF Opportunities Trust	0	--
Vanguard	0	--

13. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-09.

56% fund support · no official result

FOR 56%AGAINST 44%

The 5 asset managers below cast 56% of the shares they voted on this item FOR (45,366 for, 35,441 against).

FOR: 45,366 (56.1%)AGAINST: 35,441 (43.9%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Vote
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	43,088	0	For
Empower	0	28,833	Against
Vinva Investment Management Ltd	0	6,574	Against
CLEARWATER INVESTMENT TRUST	2,278	0	For
MILLER HOWARD INVESTMENTS INC /NY	0	34	Against

14. Amend Omnibus Stock Plan

COMPENSATION

Meeting held 2026-06-09.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 31,111 against).

AGAINST: 31,111 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	0	28,833	0	0	Against
CLEARWATER INVESTMENT TRUST	0	2,278	0	0	Against

15. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-09.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (108 for, 0 against).

FOR: 108 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	54	0	0	0	For
Tandem Financial, LLC	54	0	0	0	For

16. Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

— fund support · no official result

1 YEAR 90%10%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 11,838 (89.9%)ONE YEAR: 1,325 (10.1%)

Largest asset managers voting on “Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named execu” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	0	0	0	0	1 Year
GLENMEDE FUND INC	0	0	0	0	One Year

17. Approval of our Amended and Restated 2011 Stock Incentive Plan.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

59% Majority: yes · of votes cast

FOR 59%AGAINST 41%

FOR: 22,043,902AGAINST: 15,317,588

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 5: Approval of the Company's Amended and Restated 2011 Stock Incentive Plan.”): 22,043,902 for, 15,317,588 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 56% for, 39% against (95% of the company cast a for/against vote).

The 2 asset managers below cast 90% of the shares they voted on this item FOR (11,838 for, 1,325 against).

FOR 90%10%

FOR: 11,838 (89.9%)AGAINST: 1,325 (10.1%)

Largest asset managers voting on “Approval of our Amended and Restated 2011 Stock Incentive Plan.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	0	1,325	0	0	Against

18. Approval, on an advisory basis, of the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: no

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

40% Majority: no · of votes cast

FOR 40%AGAINST 60%

FOR: 14,752,829AGAINST: 22,595,202

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 3: Advisory vote to approve the compensation of the Company's named executive officers.”): 14,752,829 for, 22,595,202 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 37% for, 57% against (95% of the company cast a for/against vote).

The 2 asset managers below cast 90% of the shares they voted on this item FOR (11,838 for, 1,325 against).

FOR 90%10%

FOR: 11,838 (89.9%)AGAINST: 1,325 (10.1%)

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers.” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	0	1,325	0	0	Against

19. Election of Class II Director to serve until the 2028 annual meeting of stockholders: Alethia Young

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 28,757,450WITHHELD: 8,624,358

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Alethia Young”): 28,757,450 for, 8,624,358 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 73% for, 22% withheld (95% of the company cast a for/withheld vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,163 for, 0 against).

FOR 100%

FOR: 13,163 (100.0%)

Largest asset managers voting on “Election of Class II Director to serve until the 2028 annual meeting of stockholders: Alethia Young” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	1,325	0	0	0	For

20. Election of Class II Director to serve until the 2028 annual meeting of stockholders: Frank D. Lee

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 32,858,858WITHHELD: 4,522,950

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Frank D. Lee”): 32,858,858 for, 4,522,950 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 84% for, 11% withheld (95% of the company cast a for/withheld vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,163 for, 0 against).

FOR 100%

FOR: 13,163 (100.0%)

Largest asset managers voting on “Election of Class II Director to serve until the 2028 annual meeting of stockholders: Frank D. Lee” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	1,325	0	0	0	For

21. Election of Class II Director to serve until the 2028 annual meeting of stockholders: Marcelo Bigal

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 33,364,221WITHHELD: 4,017,587

Pacira Biosciences, Inc.’s own tally for this item (“Elect Director: Marcelo Bigal”): 33,364,221 for, 4,017,587 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 85% for, 10% withheld (95% of the company cast a for/withheld vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,163 for, 0 against).

FOR 100%

FOR: 13,163 (100.0%)

Largest asset managers voting on “Election of Class II Director to serve until the 2028 annual meeting of stockholders: Marcelo Bigal” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	1,325	0	0	0	For

22. Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-10 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 40,022,569AGAINST: 352,947

Pacira Biosciences, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 40,022,569 for, 352,947 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 39,347,924 outstanding shares: 100% for, 0.9% against (100% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (13,163 for, 0 against).

FOR 100%

FOR: 13,163 (100.0%)

Largest asset managers voting on “Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fisca” at Pacira Biosciences, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	11,838	0	0	0	For
GLENMEDE FUND INC	1,325	0	0	0	For

Largest Pacira Biosciences, Inc. shareholders voting in 2025-2026

Ranked by the number of Pacira Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 39,347,924 shares outstanding at the time of that meeting.

Top Pacira Biosciences, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	12.65%
2	BlackRock	11.73%
3	State Street	4.48%
4	Charles Schwab	3.55%
5	Fidelity	2.50%
6	GEODE CAPITAL MANAGEMENT, LLC	2.35%
7	Dimensional	2.06%
8	IMPAX ASSET MANAGEMENT LLC	1.91%
9	IMPAX FUNDS SERIES TRUST I	1.91%
10	Wellington	1.17%

Reported Pacira Biosciences, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Pacira Biosciences, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	17.12%	13F
Vanguard Group	12.23%	13F
Doma Perpetual Capital Management LLC	7.46%	13D
Pedro Escudero	7.46%	13D
Vanguard Portfolio Management	6.57%	13G
Dimensional Fund Advisors	5.24%	13F
D.E. Shaw	5.04%	13F
State Street	4.88%	13F
Renaissance Technologies	4.64%	13F
Goldman Sachs	3.99%	13F

Percentages above are of 39,347,924 shares outstanding, as reported by Pacira Biosciences, Inc. on its Form 10-Q dated 2026-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Pacira Biosciences, Inc.’s 10-Q dated 2026-04-29. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Pacira Biosciences, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 283 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,666 separate fund positions. Their filings are grouped here into 22 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Pacira Biosciences, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval, on an advisory basis, of the compensation of our named executive officers. — the reporting funds cast 76% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Pacira Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).